LCMS Bioanalysis of Antibody Drugs Using Fab-selective Proteolysis "nSMOL Method" -Selection of Signature Peptide -

LCMS Bioanalysis of Antibody Drugs Using Fab-selective Proteolysis "nSMOL Method" -Selection of Signature Peptide -

nSMOL (nano-surface and molecular-orientation limited proteolysis) is Shimadzu's completely new, proprietary, and innovative technique for selective proteolysis of Fab region of monoclonal antibodies. nSMOL allows analytical method development of antibody drugs independent of a variety of antibody drugs. Fab-derived peptide fragments produced by nSMOL can be precisely quantified by multiple reaction monitoring (MRM) using the Shimadzu LCMS-8050/8060 triple quadrupole liquid chromatograph mass spectrometer (TQ-LCMS). This report describes a selection protocol of signature peptides suitable for pharmacokinetic studies.

Content Type: Application

Document Number: C146-E340

Product Type: Mass Spectrometry, Liquid Chromatograph-Mass Spectrometry

keywords: nano-surface and molecular-orientation limited proteolysis, antibody drug, bioanalysis, LC/MS/MS, Pharmaceutical, LifeScience, Proteomics, LCMS-8050, LCMS-8060, nSMOL Antibody BA Kit

Language: English

File name: jpo117012.pdf

File size: 413kb

https://solutions.shimadzu.co.jp/an/s/en/lcms/jpo117012.pdf

For Research Use Only. Not for use in diagnostic procedures.

This page may contain references to products that are not available in your country.
Please contact us to check the availability of these products in your country.